{"title":"钠-葡萄糖共转运蛋白2 (SGLT2)抑制剂:综述","authors":"M. Demir, Z. Ercan, B. Erdoğan","doi":"10.51271/jccvs-0003","DOIUrl":null,"url":null,"abstract":"Sodium-glucose co-transporter-2 inhibitors are novel antihyperglycemic agents which have crucial effects on the heart and kidneys beyond their glucose-lowering features. Their main clinical benefits have been reported in individuals with type 2 diabetes mellitus, chronic kidney disease, heart failure, and proteinuria. However, adverse reactions (euglycemic ketoacidosis, kidney dysfunction, genital and urinary tract infections, hypovolemia, etc) remain to be the main object of the debate regarding their use. The recruited data have encouraged clinicians to use those medicines in individuals who fit the indications for use.","PeriodicalId":231655,"journal":{"name":"Journal of Cardiology & Cardiovascular Surgery","volume":"48 3 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2023-03-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Sodium-glucose co-transporter 2 (SGLT2) inhibitors: a brief review\",\"authors\":\"M. Demir, Z. Ercan, B. Erdoğan\",\"doi\":\"10.51271/jccvs-0003\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Sodium-glucose co-transporter-2 inhibitors are novel antihyperglycemic agents which have crucial effects on the heart and kidneys beyond their glucose-lowering features. Their main clinical benefits have been reported in individuals with type 2 diabetes mellitus, chronic kidney disease, heart failure, and proteinuria. However, adverse reactions (euglycemic ketoacidosis, kidney dysfunction, genital and urinary tract infections, hypovolemia, etc) remain to be the main object of the debate regarding their use. The recruited data have encouraged clinicians to use those medicines in individuals who fit the indications for use.\",\"PeriodicalId\":231655,\"journal\":{\"name\":\"Journal of Cardiology & Cardiovascular Surgery\",\"volume\":\"48 3 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-03-30\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Cardiology & Cardiovascular Surgery\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.51271/jccvs-0003\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Cardiology & Cardiovascular Surgery","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.51271/jccvs-0003","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Sodium-glucose co-transporter 2 (SGLT2) inhibitors: a brief review
Sodium-glucose co-transporter-2 inhibitors are novel antihyperglycemic agents which have crucial effects on the heart and kidneys beyond their glucose-lowering features. Their main clinical benefits have been reported in individuals with type 2 diabetes mellitus, chronic kidney disease, heart failure, and proteinuria. However, adverse reactions (euglycemic ketoacidosis, kidney dysfunction, genital and urinary tract infections, hypovolemia, etc) remain to be the main object of the debate regarding their use. The recruited data have encouraged clinicians to use those medicines in individuals who fit the indications for use.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
